Clinical trials: Graft vs Host Disease, open to volunteers
Graft-Versus-Host Disease, Graft-versus-leukemia
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for…
- Conditions
- Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis
- Trial name
- NCT00001529
- Testing
- G-CSF
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft vs Host Disease
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Background: Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant. cGVHD can affect multiple organs and increase risk of disability and death.
- Trial name
- NCT05531786
- Testing
- Pacritinib
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
GVHD - Graft-Versus-Host Disease
PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling…
- Trial name
- NCT07675174
- Testing
- Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwell Health
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Where
- 3 sites in Netherlands, Spain
- Volunteers
- 356 people
- Sponsor
- Sanofi
Graft-versus-leukemia, Graft vs Host Disease
Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center.
- Conditions
- Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection
- Trial name
- NCT00106925
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Graft Versus Host Disease
A New ECP Protocol for the Treatment of cGVHD
At present, cGvHD is the main cause of transplant-related morbidity in patients receiving allogeneic hematopoietic stem cell transplant (allo-HSCT).
- Trial name
- EXPRESS (NCT07918547)
- Testing
- Experimental ECP protocol
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)
Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host…
- Trial name
- TER-EYE (NCT06905834)
- Testing
- Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Graft Versus Host Disease (cGvHD)
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well.
- Trial name
- EVENT (NCT06991361)
- Testing
- EVE-Treg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sarah Nikiforow, MD
Autoimmune Disorders, Systemic Sclerosis
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and…
- Conditions
- Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus
- Trial name
- NCT06434363
- Testing
- Tafasitamab, Fludarabine phosphate, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
oGVHD, Ocular Graft Versus Host Disease
Study of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD)
This is a Phase III, multicenter, randomized, double-masked, vehicle-controlled, parallel-group clinical trial designed to evaluate the efficacy, safety, and tolerability of d-MAPPS™ Ophthalmic Solution in adult subjects with…
- Trial name
- NCT07776210
- Testing
- d-MAPPS™ Ophthalmic Solution, Matching vehicle control
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regenerative Ocular Immunobiologics LLC
Transplant Failure or Rejection of Bone Marrow (Graft vs Host Disease, GVHD)
A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
The researchers are doing this study to find out whether the combination of LBP-MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) and ruxolitinib is a safe treatment for people with graft-versus-host disease…
- Trial name
- NCT07913672
- Testing
- Ruxolitinib, LBP- MARCO
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft-Versus-Host Disease, GVHD
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
- Conditions
- Graft-Versus-Host Disease, GVHD, Undefined
- Trial name
- NCT05675930
- Testing
- Photobiomodulation Therapy
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
- Trial name
- AXemplify-357 (NCT06585774)
- Testing
- INCA034176, Corticosteroids
- Where
- 131 sites in United States, Australia and 11 more
- Volunteers
- 240 people
- Sponsor
- Incyte Corporation
T-cell Lymphoma, Graft Versus Host Disease
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have undergone stem cell transplantation for T-cell lymphoma.
- Conditions
- T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma
- Trial name
- NCT07356245
- Testing
- Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Chronic Graft vs. Host Disease
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Background: Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT).
- Trial name
- NCT00092235
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- National Cancer Institute (NCI)
Ocular Graft Versus Host Disease
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence…
- Trial name
- NCT07118254
- Testing
- rhPRG4 450ug/ml, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Lubris Bio Pty Ltd
Chronic Graft Versus Host Disease
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older.
- Trial name
- NCT07135973
- Testing
- Belumosudil
- Volunteers
- 26 people
- Sponsor
- Sanofi
Graft-versus-host Disease (GVHD)
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood…
- Trial name
- NCT06615050
- Testing
- Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux)
- Where
- 30 sites in United States
- Volunteers
- 572 people
- Sponsor
- Incyte Corporation
Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell…
- Conditions
- Chronic Graft Versus Host Disease, Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
- Trial name
- NCT07535008
- Testing
- Dental Cleaning, Dental Plaque sampling
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fred Hutchinson Cancer Center
Steroid Refractory Graft Versus Host Disease
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
- Trial name
- NCT07576699
- Testing
- CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.